PharmiWeb.com - Global Pharma News & Resources
08-Jan-2019

Global Glioma Therapeutics Market: Analysis & Forecast 2019-2023 - Strategic Alliances to Drive Growth - ResearchAndMarkets.com

The "Global Glioma Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The glioma therapeutics market will register a CAGR of more than 9% by 2023.

Strategic alliances to drive growth in the market

Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma.

Expected approval of late-stage pipeline molecules

As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.

Availability of alternative therapies

Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients' inclination toward the surgical and radiation treatment options.

Key Players

  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis

For more information about this report visit https://www.researchandmarkets.com/research/97lwgq/global_glioma?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005842/en/

Editor Details

Last Updated: 08-Jan-2019